Android app on Google Play

Amarin (AMRN) Vascepa Pricing Leak?

December 3, 2012 3:21 PM EST Send to a Friend
Amarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.

GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although the website has since been updated and the prices removed.

Investors were taken off-guard given the fact that Amarin hasn't even disclosed what strategy it will use to launch the FDA-approved triglyceride lowering drug. The company will either go it alone, partner with a large pharma or get acquired by a large pharma.

Recently the company delayed hiring Vascepa sales reps until early December, which has some speculating a takeover is more likely. However, an FDA decision on NCE status for Vascepa is considered to be a major sticking point for potential suitors. After months of delays on NCE status, a decision could finally come before the next Orange Book update date of December 14.

The company did not respond to a question from StreetInsider.com about the
GoodRx pricing.





You May Also Be Interested In


Related Categories

FDA, Insiders' Blog

Add Your Comment